当前位置： SCI文献检索 > CURRENT MEDICAL RESEARCH AND OPINION期刊下所有文献 > Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.

Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.

Abstract：

BACKGROUND:The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines development group examined the properties of oral H(1)-antihistamines and made proposals about an 'optimal' drug. Several criteria should be met by oral H(1)-antihistamines in terms of their pharmacological, and clinical efficacy and safety profiles. OBJECTIVE:Bilastine, a new H(1)-antihistamine, has been approved in 28 European countries for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children older than 12 years. To determine its potential place in therapy in the treatment of allergic rhinitis, this manuscript examines whether bilastine meets the criteria defined in the European Academy of Allergy and Clinical Immunology (EAACI)/ARIA proposals for oral H(1)-antihistamines. METHODS:The optimal properties of oral H(1)-antihistamines and current ARIA recommendations for their use in allergic rhinitis are presented, as well as relevant pharmacological and clinical data for bilastine obtained from the published literature that specifically address the defined criteria. RESULTS:Bilastine is a potent inhibitor of the histamine H(1) receptor. Data from preclinical studies have confirmed its selectivity for the histamine H(1) receptor over other receptors, and demonstrated antihistaminic properties in vitro and in vivo. Bilastine does not interfere with the cytochrome P450 system and is devoid of cardiac side effects. Studies in healthy volunteers and patients have shown that bilastine does not affect driving ability, cardiac conduction or alertness. In large pivotal randomized, placebo-controlled trials (RCTs), bilastine had a favourable safety profile. Bilastine 20 mg once daily improved all nasal and ocular symptoms of allergic rhinitis with greater efficacy than placebo and comparable to that of cetirizine and desloratadine. Moreover, bilastine was shown to improve quality of life, an important outcome of RCTs in allergic diseases. There were no significant changes in laboratory tests, electrocardiograms or vital signs. A potential limitation of this assessment of bilastine is that it is a literature-based review and the findings are dependent upon the quality of the published evidence. CONCLUSIONS:Bilastine meets current EAACI/ARIA criteria for medications used in the treatment of allergic rhinitis.

journal_name

Curr Med Res Opin

journal_title

Current medical research and opinion

authors

Bousquet J,Ansótegui I,Canonica GW,Zuberbier T,Baena-Cagnani CE,Bachert C,Cruz AA,González SN,Kuna P,Morais-Almeida M,Mullol J,Ryan DP,Sánchez-Borges M,Valiente R,Church MK

doi

10.1185/03007995.2011.648263

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

131-9

issue

eissn

0300-7995

issn

1473-4877

journal_volume

pub_type

杂志文章,评审

在线工具

Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.